Bliss GVS Pharma Limited shareholders approved the declaration of a final dividend of ₹1.00 per equity share for the financial year ended March 31, 2026, at its 41st Annual General Meeting held on July 15, 2026. The meeting, conducted via video conferencing, also saw the re-appointment of Mr. Narsimha Shibroor Kamath as Managing Director & CEO and the adoption of the audited financial statements for FY26. The voting results were disclosed to the stock exchanges in compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting Outcomes

All three ordinary resolutions presented at the AGM were passed. The adoption of the audited standalone and consolidated financial statements received 99.99% approval, with 65,393,771 votes in favour and 3,098 against. The resolution to declare the final dividend of 100%, or ₹1.00 per share on a face value of ₹1 each, was approved with 100% of votes polled in favour. The re-appointment of Mr. Narsimha Shibroor Kamath (DIN: 00140593) as Managing Director & CEO was approved by 97.68% of the votes polled, with Public Institutions holding 14.45% of their votes against the resolution.

Procedural Details

The remote e-voting process commenced on July 12, 2026, and concluded on July 14, 2026, facilitated by Central Depository Services (India) Limited (CDSL). Mr. Vijay Yadav, Partner of AVS & Associates, served as the Scrutinizer for the meeting. The record date for determining shareholder eligibility was July 08, 2026, with a total of 47,336 shareholders on record. The meeting was chaired by Mr. Nandkumar Chodankar, Chairman & Independent Director.

Bliss GVS Pharma has approved a leadership transition, appointing Rahul Adakmol as Chief Executive Officer effective July 15, 2026. The Board of Directors also appointed Santosh Parab as an Additional Director in the capacity of Non-Executive Non-Independent Director effective July 03, 2026. These decisions were taken during a meeting held on July 03, 2026, via Video Conferencing.

Key Appointments

The appointment of Mr. Santosh Parab (DIN: 01622988) adds over 35 years of experience in audit, taxation, and corporate finance to the Board. His profile indicates extensive work with financial institutions such as State Bank of India, ICICI Bank, and Kotak Mahindra Bank. He previously worked with Bliss GVS Pharma Limited, bringing prior familiarity with the company's operations.

Mr. Rahul Adakmol steps into the role of Chief Executive Officer with a background in chemical engineering and an MBA from IIM Bangalore. He brings over 22 years of experience, having held senior leadership positions at Bharat Serums and Vaccines, Dr. Reddy's Laboratories, and Reliance Industries. His expertise spans sales, marketing, manufacturing, and global market expansion across more than 70 countries.

Leadership Transition

The changes follow the resignation of Mr. Narsimha Shibroor Kamath from the position of Chief Executive Officer. Mr. Kamath stepped down effective the close of business hours on July 14, 2026. In his resignation letter, he stated that the decision reflects a belief that the time is right for a leadership transition to guide the company through its next phase of growth. He will continue to serve as the Managing Director of the company.

The Board's decisions were based on the recommendations of the Nomination and Remuneration Committee. The meeting concluded at 04:07 p.m. on July 03, 2026. The disclosures were made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Summary of Appointments